

# Sexual Health and its Impact On Quality of Life of Patients with Lung Cancer

Mafalda Costa, Catarina Lopes Fernandes, Joana Leite, Marta Vilaça, Fernanda Estevinho, Helena Magalhães Medical Oncology Department - Pedro Hispano Hospital, Matosinhos, Portugal

CONTACT INFO Mafalda Costa mafallda.teixeiracosta@ulsm.min-saude.pt

## INTRODUCTION

- The prevalence of sexual dysfunction in lung cancer patients is still unknown and little reported in our daily practice.
- With the emerging new treatments and improved survival, more studies are **needed** to acknowledge the impact of lung cancer (LC) diagnosis and treatments on the quality of sexual life.

#### METHODS

- This cross-sectional study evaluated the sexual activity and satisfaction of LC patients treated at the Medical Oncology department of our center.
- ◆ A male and female version of a multiplechoice questionnaire in Portuguese, wondering about sexual activity and satisfaction over the "past 30 days "was specifically designed for LC patients by the study team.



- Age > 18 years old diagnosed with LC able to read
- completed at least 1 mo of systemic treatment
- Descriptive analysis was performed using SPSS® absolute and relative frequencies, means and SD for continuous variables when presented with a normal distribution, or median and quartiles instead when the data did not have a normal distribution.


### REFERENCES

Florez, N.; et al. Sexual Health Assessment in Women with Lung Cancer study: Sexual health in women with lung cancer. Cancer 2024, 130, 375–384. 2. Ospina Serrano,; et al. 251P Sexual dysfunction in patients with lung cancer: Interim analysis of the LUDICAS study. ESMO Open 2024, 9, 102713

Table 1,2. patient disease and treatment characteristics.

<b>ble 1,2.</b> patient disease and	
Characteristic	N (%)
All	45 (100)
Sex	
Male – n (%)	31 (69)
Age Median (range)	66 (46-87)
ECOG PS (0 and 1)	· / /
	42 (93)
Former smokers	17 (38)
Active smokers	15(33)
COPD or emphysema	8 (18)
Anxiety or depression	3 (7)
	0(1)
NSCLC	
Adenocarcinoma	29 (64)
Squamous cell	10 (22)
Adenosquamous	1 (2)
NOS	1 (2)
	4 (0)
SCLC	4 (9) 31 (64)
Disease stage Stage IV	31 (04)
Oldge IV	
Median time since	11 months
Median time since diagnosis	11 months (2-126)
diagnosis	(2-126)
diagnosis Characteristic	
diagnosis	(2-126) N (%)
diagnosis Characteristic Systemic treatment	(2-126)
diagnosis Characteristic Systemic treatment TKI	(2-126) <i>N (%)</i> 9 (20)
diagnosis Characteristic Systemic treatment TKI Immunotherapy	(2-126) <i>N (%)</i> 9 (20) 12 (27)
diagnosis Characteristic Systemic treatment TKI Immunotherapy Chemoimmunotherapy	(2-126) <i>N (%)</i> 9 (20) 12 (27) 8 (18)
diagnosis Characteristic Systemic treatment TKI Immunotherapy Chemoimmunotherapy Chemotherapy	(2-126) <i>N</i> (%) 9 (20) 12 (27) 8 (18) 13 (29)
diagnosis Characteristic Systemic treatment TKI Immunotherapy Chemoimmunotherapy Chemotherapy Chemoradiotherapy Bispecific antibodies	(2-126) <i>N</i> (%) 9 (20) 12 (27) 8 (18) 13 (29) 2 (4)
diagnosis Characteristic Systemic treatment TKI Immunotherapy Chemoimmunotherapy Chemotherapy Chemoradiotherapy Bispecific antibodies Radiotherapy	(2-126) <i>N</i> (%) 9 (20) 12 (27) 8 (18) 13 (29) 2 (4) 1 (2)
diagnosis Characteristic Systemic treatment TKI Immunotherapy Chemoimmunotherapy Chemotherapy Chemoradiotherapy Bispecific antibodies Radiotherapy SRS	(2-126) <b>N (%)</b> 9 (20) 12 (27) 8 (18) 13 (29) 2 (4) 1 (2) 3 (7)
diagnosis Characteristic Systemic treatment TKI Immunotherapy Chemoimmunotherapy Chemotherapy Chemoradiotherapy Bispecific antibodies Radiotherapy SRS Holocraneal RT	(2-126) <b>N (%)</b> 9 (20) 12 (27) 8 (18) 13 (29) 2 (4) 1 (2) 3 (7) 5 (11)
diagnosis Characteristic Systemic treatment TKI Immunotherapy Chemoimmunotherapy Chemotherapy Chemoradiotherapy Bispecific antibodies Radiotherapy SRS Holocraneal RT SBRT lung	(2-126) <b>N (%)</b> 9 (20) 12 (27) 8 (18) 13 (29) 2 (4) 1 (2) 3 (7) 5 (11) 3 (7)
diagnosis Characteristic Systemic treatment TKI Immunotherapy Chemoimmunotherapy Chemotherapy Chemoradiotherapy Bispecific antibodies Radiotherapy SRS Holocraneal RT	(2-126) <b>N (%)</b> 9 (20) 12 (27) 8 (18) 13 (29) 2 (4) 1 (2) 3 (7) 5 (11)
diagnosis Characteristic Systemic treatment TKI Immunotherapy Chemoimmunotherapy Chemotherapy Chemoradiotherapy Bispecific antibodies Radiotherapy SRS Holocraneal RT SBRT lung RT lung	(2-126) <b>N (%)</b> 9 (20) 12 (27) 8 (18) 13 (29) 2 (4) 1 (2) 3 (7) 5 (11) 3 (7)
diagnosis Characteristic Systemic treatment TKI Immunotherapy Chemoimmunotherapy Chemotherapy Chemoradiotherapy Bispecific antibodies Radiotherapy SRS Holocraneal RT SBRT lung	(2-126) <b>N (%)</b> 9 (20) 12 (27) 8 (18) 13 (29) 2 (4) 1 (2) 3 (7) 5 (11) 3 (7) 20 (44)
diagnosis Characteristic Systemic treatment TKI Immunotherapy Chemoimmunotherapy Chemotherapy Chemoradiotherapy Bispecific antibodies Radiotherapy SRS Holocraneal RT SBRT lung RT lung	(2-126) <b>N (%)</b> 9 (20) 12 (27) 8 (18) 13 (29) 2 (4) 1 (2) 3 (7) 5 (11) 3 (7) 20 (44) 3 (7)
diagnosis Characteristic Systemic treatment TKI Immunotherapy Chemoimmunotherapy Chemotherapy Chemoradiotherapy Bispecific antibodies Radiotherapy SRS Holocraneal RT SBRT lung RT lung Surgery Lobectomy	(2-126) <b>N (%)</b> 9 (20) 12 (27) 8 (18) 13 (29) 2 (4) 1 (2) 3 (7) 5 (11) 3 (7) 20 (44)
diagnosis Characteristic Systemic treatment TKI Immunotherapy Chemoimmunotherapy Chemotherapy Chemoradiotherapy Bispecific antibodies Radiotherapy SRS Holocraneal RT SBRT lung RT lung Surgery Lobectomy Bilobectomy	(2-126) $N (%)$ 9 (20) 12 (27) 8 (18) 13 (29) 2 (4) 1 (2) 3 (7) 5 (11) 3 (7) 20 (44) 3 (7) 1 (2)





# CONCLUSIONS

Sexual dysfunction is prevalent among LC patients and several factors related to the disease and treatment contribute to this. It is important to be aware of the **impact on quality of life** and implement assessment strategies and interventions to maintain a healthy sexual life for LC patients.